GSK (BSX) stock surged early Wednesday after the pharma giant reported adjusted earnings of 58 cents per share on $9.48 billion in fourth-quarter sales.
↑ X NOW PLAYING The Weight-Loss Drug Market Is Hot. Which Medical Stock Will Win The Battle For Supremacy?Analysts polled by FactSet expected GSK to earn 49 cents per share on $9.54 billion in sales.
In the year-earlier period, GSK reported earnings of 74 cents a share on $10.25 billion in sales.
For the year, the company guided to 3% to 5% sales growth and 6% to 8% core operating growth. The company also projects 6% to 8% growth in core earnings per share. Analysts forecasted earnings of $4.54 a share and $42.64 billion in sales.
GSK also bumped its 2031 sales outlook and now projects more than 40 billion pounds in sales, up from more than 38 billion pounds previously. That translates to roughly $50.05 billion, up from $47.55 billion, based on today's exchange rates.
In premarket trades on the stock market today, GSK stock charged 6.5% higher to 37.09.
More to follow.
YOU MAY ALSO LIKE:
Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares
RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
Want To Get Quick Profits And Avoid Big Losses? Try SwingTrader
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。